Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease
-
Narrated by:
-
By:
About this listen
In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:
- The available biologic therapies that specifically target IL-13
- Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm
- How these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitors
- A detailed patient case to highlight take home points
Presenter
Andrew F. Alexis, MD, MPH
Professor of Clinical Dermatology
Weill Cornell Medical College
New York, New York
Daniel C. Butler, MD
Assistant Dean Student Affairs
University of Arizona College of Medicine – Tucson
Tucson, Arizona
Shawn G. Kwatra, MD
Dr. Joseph W. Burnett Endowed Professor and Chair
Department of Dermatology
University of Maryland School of Medicine
Baltimore, Maryland
Program page:
https://bit.ly/4kTP04D
No reviews yet